NEW YORK (Reuters Health) – In postmenopausal women with low bone mass, continuous treatment with denosumab — 2 doses per year for up to 6 years — is well tolerated and results in progressive gains in bone mineral density (BMD), results of an extension study indicate.
Denosumab (Prolia, Amgen)...